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Oral  squamous  cell  carcinoma  (OSCC)  is the  most  common  malignant  tumor  in the  oral  cavity  and  the head
and neck  region.  Gingival  squamous  cell carcinomas  (SCCs)  frequently  invade  the  maxilla  or  the mandibu-
lar bone  and  are  associated  with  poor  prognosis.  Recent  ﬁndings  suggest  that  osteoclasts,  rather  than
OSCC  cells,  mediate  invasion  to the  bone.  Nuclear  factor-B  (NF-B)  is  constitutively  activated  in  OSCCs
and  is  involved  in promoting  the  invasive  characteristics  of  OSCC.  NF-B  activation  is  also  important
for  receptor  activator  of  NF-B  ligand  (RANKL)-induced  osteoclastogenesis.  NF-B  inhibitors  suppress
proliferation  and  stimulate  apoptosis  of OSCC  cells  in vitro  and  in  vivo, as  well  as  inhibit  matrix  metal-one invasion
ral squamous cell carcinoma
loproteinase  (MMP)  production  in OSCC.  Furthermore,  NF-B  inhibitors  have  been  shown  to  suppress
osteoclastogenesis  by  reducing  RANKL  expression  in  animal  models.  Thus,  inhibition  of  NF-B  activity
may  constitute  a promising  therapeutic  approach  to  treat  bone-invasive  OSCC.  In this  review,  we  discuss
recent  ﬁndings,  which  suggest  that bone  invasion  in  OSCC  is  mediated  via  NF-B  signaling  and  may  be
successfully  prevented  by NF-B  inhibition.
© 2015  Japanese  Stomatological  Society.  Published  by Elsevier  Ltd.  All  rights  reserved.ontents
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. Introduction
Oral squamous cell carcinoma (OSCC) is a malignant cancer of
he head and neck region and is the sixth most common cancer
n the world, with approximately 500,000 new cases projected
nnually [1]. Studies conducted in Japan demonstrated a dra-
atic increase in oral cancer incidence for both sexes with a
.4-fold increase observed in males and 3.8-fold increase observed
n females between 1965 and 1999 according to the Osaka Can-
er Registry database [2]. The treatment of OSCC involves surgical
esection, radiotherapy, chemotherapy, or a combination of these
reatments. Despite advances in treatment, the 5-year survival rate
or OSCC has not improved signiﬁcantly and remains at 50–55%
3,4]. In particular, gingival squamous cell carcinoma frequently
nvades the maxilla or the mandible bone, which is a critical fac-
or for poor prognosis as it leads to metastasis [5]. The presence of
andibular invasion is an important criterion for deciding whether
andibulectomy is necessary. According to the American Joint
ommittee on Cancer Classiﬁcation, mandibular invasion is the
ost advanced primary stage (T4) and overall stage (IV) for these
umors. The treatment outcomes of these lesions are typically poor,
ith nearly 70% of cases recurring at the primary lesion site and
ltimately leading to death [6].
The transcription factor nuclear factor-B (NF-B) regulates
he expression in a wide variety of genes that are involved in
mmune and inﬂammatory responses, proliferation, tumorigene-
is, and cell survival [7,8]. Accumulating evidence suggests that
he NF-B signaling pathway contributes to carcinogenesis and the
cquisition of malignant characteristics, such as increased invasion,
urvival, chemoresistance, and angiogenesis in a number of can-
er types, including OSCC [9–11]. The activation of NF-B induces
pithelium–mesenchyme transition (EMT) in OSCC [12]. Consti-
utive activation of NF-B has been reported in oral cancer, and
levated expression of NF-B correlates with enhanced invasion
nd metastasis in OSCC [9–11]. NF-B has been reported to selec-
ively enhance the expression of pro-inﬂammatory cytokines, such
s interleukin (IL)-1, IL-6, and IL-8 as well as the expression of
egradation enzymes, such as matrix metalloproteinase (MMP)-
 [13,14], suggesting that NF-B may  signiﬁcantly contribute to
umor progression and metastasis in OSCC via either direct or indi-
ect mechanisms.
Recent studies have established that bone resorption by osteo-
lasts is an important step in the process of bone invasion and
etastasis in several types of malignancies [15]. Therefore, to pre-
ent bone invasion by OSCC cells, it is absolutely necessary to
nderstand the molecular mechanisms by which OSCC regulates
steoclastogenesis. Three proteins are crucial for osteoclastogen-
sis, including the receptor activator of NF-B ligand (RANKL),
ts receptor RANK, and its decoy receptor osteoprotegerin (OPG).
he RANKL/RANK interaction induces osteoclastogenesis, while
PG prevents this process in vitro and in vivo [16,17]. Although
hese proteins are known to be involved in normal bone devel-
pment, they have also been shown to contribute to pathological
one metabolic processes, such as osteolysis, which is associated
ith the progression of malignant tumors at the bone site [18,19].
inding of RANKL to RANK activates several intracellular signaling
athways, and activation of NF-B is an important step for RANKL-
nduced osteoclastogenesis. Inhibition of NF-B by selective NF-B
nhibitors prevents RANKL-induced osteoclastogenesis in vitro and
nﬂammatory bone loss in vivo [20–22]. Therefore, the inhibition of
F-B activity may  constitute a promising approach for the treat-
ent of bone invasion by OSCC.
In this review, we ﬁrst summarize the NF-B signaling path-
ay and describe recent ﬁndings from our laboratory and others
hat highlight a role for NF-B signaling in OSCC development
nd osteoclastogenesis. Finally, we discuss the possibility thatrnational 13 (2016) 1–6
inhibition of NF-B signaling might successfully prevent bone inva-
sion by OSCC.
2. Regulatory mechanisms of NF-B signaling pathway
2.1. Structures of NF-B/Rel family, IB family, and IKK complex
NF-B was  originally identiﬁed as a transcription factor that
bound to the enhancer region of the immunoglobulin  light chain
promoter in B cells [23]. The NF-B family of transcription fac-
tors consists of ﬁve ubiquitously expressed proteins in mammals,
including p65 (RelA), c-Rel, RelB, NF-B1 (p105/p50), and NF-B2
(p100/p52), which form various homo- and heterodimers (Fig. 1)
[8,24]. All ﬁve members share an N-terminal domain of 300 amino
acids, designated as the Rel homology domain (RHD), which is
derived from the retroviral oncoprotein v-Rel and is responsible for
DNA binding, dimerization, and the interaction with IB (inhibitor
of B) proteins. Three members, p65, c-Rel and RelB, contain C-
terminal transcriptional activation domains (TAD) that are crucial
for their ability to induce target gene expression. p65, c-Rel, and
RelB are synthesized as mature proteins, whereas NF-B1 and NF-
B2 are synthesized as the large precursor proteins p105 and p100,
which undergo processing to generate the mature NF-B subunits
p50 and p52, respectively. The C-terminal regions of p105 and p100
contain ankyrin repeats that are selectively degraded by the ubiq-
uitin/proteasome pathway. Thus, the homodimers of p50 and p52
lack TADs, and therefore have no intrinsic ability to drive transcrip-
tion as transcriptional repressors. However, the p65:p50, c-Rel:p50,
and RelB:p52 heterodimers function as transcriptional activators
[8,24].
The activation of NF-B signaling is regulated by IB proteins,
such as IB, IB, and IB, and the precursors p105 (NF-B1)
and p100 (NF-B2), which are characterized by multiple ankyrin
repeat domains and the ability to bind NF-B dimers. In unstim-
ulated cells, NF-B dimers are maintained in the cytosol complex
with IB proteins (Fig. 1) [24,25]. Activation of NF-B is achieved
through phosphorylation of IBs at conserved “destruction box”
serine residues (DSGXXS), which leads to recognition by TrCP
proteins [24,25].
The IB kinase (IKK) is an enzyme complex that is involved
in modulating the cellular response [8,24,25]. The IKK complex
consists of three subunits that are each encoded by a separate
gene, IKK  ˛ (also known as IKK1), IKK  ˇ (also known as IKK2), and
NF-B essential modulator (NEMO) (also known as IKK) (Fig. 1).
Together, the - and -subunits are catalytically active, whereas
NEMO serves a regulatory function. IKK and IKK, 85 and 87 kDa,
respectively, have high sequence homology and contain an N-
terminal kinase domain, a dimerization domain, and a C-terminal
NEMO-binding domain (NBD) [26]. Despite the structural similarity
of IKK and IKK, biological and genetic studies indicate that IKK
is the dominant kinase involved in IB phosphorylation [27–31].
IKK-deﬁcient mice present a phenotype similar to that of p65-
deﬁcient mice, which die at E13.5 from severe liver damage due
to massive apoptosis, reinforcing the importance of IKK in IB
phosphorylation. By contrast, IKK-deﬁcient mice die perinatally
with multiple morphological defects [32,33]. Recent studies have
shown that IKK is involved in an alternative NF-B pathway that
regulates the RelB/p52 dimer [34]. Mice deﬁcient in the third com-
ponent, NEMO, die at E12.5-E13.0 from severe liver damage due
to massive apoptosis, suggesting that NEMO is indispensable for
activation of NF-B signaling [35].2.2. Regulatory mechanisms of NF-B signaling
NF-B is activated by two distinct pathways, referred to as the
“classical or canonical” or “alternative or non-canonical” NF-B
E. Jimi et al. / Oral Science International 13 (2016) 1–6 3
Fig. 1. Schematic representation of the NF-B/IB protein family and the IKK family. Members of the NF-B/IB protein family and the IKK family are shown. The number of
amino  acids in each protein is indicated on the right. Presumed sites of cleavage for p105 (
TAD:  transcriptional activation domain, LZ: leucine zipper, GRR: glycine-rich repeat, AN
domain, SDD: scaffolding and dimerization domain, NBD: NEMO-binding domain.
Fig. 2. The classical and alternative NF-B signaling pathways. The classical (canon-
ical)  pathway is activated by a large number of agonists, such as TNF-, IL-1,
lipopolysaccharide and T-cell receptors. Activation of this pathway depends on
the  IKK complex, which phosphorylates IB to induce rapid degradation. This
pathway is essential for immune responses, inﬂammation, tumorigenesis, and cell
survival. The alternative (non-canonical) pathway is activated by a limited number
of agonists, which are involved in secondary lymphoid organogenesis, mature B-
cell function, and adaptive immunity. This pathway requires NF-B-inducing kinase
(
i
a
r
w
s
cNIK) and IKK to promote processing of the p100 precursor into p52, which results
n  the dimerization and activation of the p52/RelB heterodimer.
ctivation pathway (Fig. 2) [8,24]. These pathways are differentially
egulated by IKK and IKK. The latent NF-B, which complexes
ith IBs, resides in the cytoplasm. In response to a variety of
timuli, such as tumor necrosis factor (TNF)-,  IL-1 or lipopolysac-
haride (LPS) treatment, IB is phosphorylated at serines 32 andamino acid 433) and p100 (amino acid 447) are shown. RHD: Rel homology domain,
K: ankyrin repeat, PEST: PEST domain, CC: coiled-coil domain, ULD: ubiquitin-like
36, while IB is phosphorylated at serines 19 and 21 by the
activated IKK complex, mainly IKK, which leads to their ubiquitin-
ation and degradation by the 26S proteasome. Degradation of IB
and IB ensures NF-B dimers, mainly p65:p50, translocation to
the nucleus and regulate gene expression.
By contrast, the alternative NF-B pathway depends on IKK
and is independent of NEMO [34]. The alternative NF-B pathway is
activated by a select group of tumor necrosis factor receptor (TNFR)
superfamily members, including CD40, lymphotoxin- receptor
(LTR), and receptor activator of NF-B (RANK). This pathway
requires NF-B-inducing kinase (NIK) and IKK to induce the slow
processing of p52 from p100, leading to the dimerization and acti-
vation of the p52/RelB heterodimer [34,36].
3. The role of NF-B in cancer development
NF-B is thought to play a role in cancer development because
v-Rel, a retroviral homolog of the NF-B subunit c-Rel, functions
as an oncogene. However, mutations in the NF-B pathway are
rarely observed in human solid tumors. Recently, a common inser-
tion (ins)/deletion (del) polymorphism (−94ins/del ATTG) in the
NFKB1 (NF-B1/p50) promoter was found [37]. The promoter of
the mutant ins allele was  characterized with twofold higher activ-
ity than that of the allele containing a del in the NFKB1 promoter.
Lin et al. reported a signiﬁcant association between the ins poly-
morphism in the NFKB1 promoter and the risk of OSCC in an older
subset of male areca chewers [38]. However, no relationship was
detected between the NFKB1 allotype or genotype and the status of
malignancy of OSCC patients. However, Lin et al. reported that the
mutant NFKB promoter regions: NFKB1 −94 ATTG2, NFKBIA (IB)
−826A, and −881G alleles were associated with oral carcinogenesis
[39]. Together, this work suggests that the combination of NFKB1
or NFKBIA gene polymorphisms and environmental carcinogenesis
may  be related to an increased risk of oral cancer. Furthermore,
the genetic polymorphism of NFKBIA −519 appears to represent a
predictive factor for metastatic OSCCs [39].
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The NF-B signaling pathway is activated in many cancers,
ncluding OSCC, and contributes to the acquisition of malignant
haracteristics, such as increased invasion, survival, chemoresis-
ance, and angiogenesis of OSCC [9–14]. A previous report showed
hat elevated expression of NF-B correlates with enhanced inva-
ion and metastasis of OSCC [13]. Thus, activation of NF-B pathway
s important for the development of OSCCs in two  distinct roles.
irst, activation of NF-B regulates cytokine expression, which
s involved in stimulating cell proliferation, cell survival, matrix
egradation, or angiogenesis. Second, NF-B activation in the cells
urrounding OSCC promotes the acquisition of malignant char-
cteristics in OSCC. For example, activation of NF-B has been
hown to induce tumor-inﬁltrating immune cells and secretion of
ytokines that positively reinforce NF-B signaling in OSCC cells.
linically, increased levels of the NF-B-target, IL-6, have been
ound in serum and saliva of OSCC patients compared with age-
atched healthy volunteers [40]. In addition, increased expression
f IL-1, an NF-B target gene that activates NF-B signaling, has
een associated with the severity of oral malignant transformation
n a mouse OSCC model [41]. IL-1 also promotes angiogenesis,
MT, and migration of OSCC cells. In addition, mice engineered
o overexpress IKK within the stratiﬁed epithelia consistently
evelop inﬂammation and spontaneous tumors in the oral cav-
ty, and chemical induction of tumors within this mouse model
isplayed higher malignant activity in the presence of IKK over-
xpression [42].
. The role of NF-B on bone resorption
Osteoclasts are multinucleated cells that are responsible for
one resorption. Studies published during 1997–1998 revealed an
mportant role for the RANKL, RANK, and OPG proteins in osteo-
lastogenesis. Osteoclast precursors that express RANK, which is
 TNFR family member, recognize RANKL and differentiate into
steoclasts in the presence of the macrophage colony-stimulating
actor (M-CSF) [16,17]. The in vivo signiﬁcance of the RANKL-RANK
ignaling pathway has been demonstrated via targeted disruption
f either gene in mice, which leads to severe osteopetrosis due to a
omplete lack of osteoclasts [43,44]. The RANKL-RANK interaction
ctivates several intracellular pathways that promote osteoclast
ifferentiation, including nuclear factor of activated T cells (NFAT),
os, NF-B, or mitogen-activated protein kinases.
Similar to RANKL- or RANK-deﬁcient mice, mice lacking
oth NF-B1 (p50/p105) and NF-B2 (p52/p100) develop severe
steopetrosis, suggesting that NF-B plays a critical role in osteo-
last differentiation by signaling downstream of RANK [45,46].
urthermore, speciﬁc deletion of IKK in osteoclast precursors has
een shown to drive osteopetrosis [47]. We  previously identiﬁed
n N-terminal -helical region of NEMO that associates with a
exapeptide sequence within the extreme carboxyl-terminus of
KK and IKK, termed the NBD. A cell-permeable peptide that
pans the NBD (NBD peptide) was shown to disrupt the association
f NEMO with IKK, block NF-B activation, and suppress inﬂam-
atory responses in animal models of inﬂammation [26]. Thus, the
BD peptide might represent an attractive target for the develop-
ent of drugs aimed at disrupting the IKK complex. This peptide
nhibited RANKL-induced osteoclastogenesis, NF-B-binding activ-
ty, and transcriptional activity in osteoclast precursors, but not
-Jun N-terminal protein kinase activity induced by RANKL. Injec-
ion of the NBD peptide into collagen-induced arthritis (CIA) models
educed CIA severity by inhibiting TNF- and IL-1 production,
brogating joint swelling, and reducing bone and cartilage destruc-
ion [20]. Dai et al. have also reported that the NBD peptide, coupled
o a different cell-permeable sequence, blocks RANKL-induced
steoclastogenesis in vitro and bone erosion in serum-transferredrnational 13 (2016) 1–6
arthritis [21]. These results indicate that inhibition of NF-B rep-
resents a useful therapeutic strategy to prevent bone invasion by
OSCC by inhibiting osteoclastogenesis.
5. The effect of selective NF-B inhibitors on bone invasion
by OSCC
Bone invasion by OSCC is a complex process that consists of a
multistep cascade of events, which are regulated by a wide vari-
ety of molecules that contribute to OSCC cell growth and OSCC cell
invasion of jawbones, including degradation of the extracellular
matrix of gingiva and osteoclastogenesis [48]. As described previ-
ously, several in vitro and in vivo animal experiments have shown
that OSCC cells produce several inﬂammatory cytokines, including
IL-1, IL-6, IL-11, and TNF, which regulate RANKL or OPG expres-
sion during osteoclastogenesis and MMPs  for matrix degradation
[9–14]. The therapeutic potential of NF-B inhibition in OSCC has
been extensively studied using biochemical approaches [49,50].
The expression of a dominant negative IB mutant, which lacks
regulatory serine phosphorylation sites, was shown to inhibit sur-
vival, pro-inﬂammatory cytokine expression, and tumor growth
in vivo [51,52]. Similarly, genetic suppression of NF-B activation
by small hairpin RNA-mediated targeting of p65-inhibited prolif-
eration of OSCC [53]. Several pharmacological inhibitors of NF-B
activation have been demonstrated to effectively reduce growth
and invasion by OSCC in vitro and experimental models [13,54].
Bortezomib is a proteasome inhibitor that has been clinically
approved for the treatment of refractory multiple myeloma and
mantle cell lymphoma worldwide [55,56]. A number of clinical tri-
als have investigated the efﬁcacy of bortezomib for the treatment of
solid tumors. Although bortezomib inhibits NF-B activity and pro-
liferation of OSCC in vitro, in vivo effects are less profound because
irradiation activates NF-B in OSCC cells by superoxide production
to protect cell death [57]. However, a combined treatment with
bortezomib and irradiation was  shown to suppress NF-B activity
and cell growth more effectively in vitro and in vivo compared with
irradiation alone. The combined treatment signiﬁcantly inhibited
irradiation-induced production of IL-6, IL-8, and vascular endothe-
lial growth factor (VEGF); decreased blood vessel formation in
tumor tissues; and suppressed irradiation-induced antiapoptotic
genes [57]. Taken together, bortezomib may  be an effective treat-
ment for OSCC by suppressing angiogenesis and inducing apoptosis
of OSCC through inhibition of NF-B.
Curcumin, also known as turmeric, is a polyphenol derived from
the plant Curcuma longa that possesses anticancer, antioxidant, and
anti-inﬂammatory effects [58]. Curcumin was shown to inhibit pro-
liferation and induce apoptosis in OSCC through suppression of
NF-B activation and NF-B-related gene expression, including Bcl-
2, cyclin D1, cyclooxygenase-2, and MMP-9 [59,60]. Importantly,
however, curcumin did not affect the growth of normal oral epithe-
lial cells. Furthermore, a combined treatment with curcumin and
irradiation led to superior suppression of NF-B activity and cell
growth in vitro and in vivo compared with curcumin or irradia-
tion alone [61,62]. Together, these reports indicate that curcumin
may  function as a radiosensitizer of OSCC cells by inhibiting NF-B
activation, without negligible toxicity.
Animal models are essential to investigate the mechanisms that
underlie bone invasion by OSCC. SCCVII is a malignant tumor cell
line derived from mice that has been used to develop an ani-
mal  model of oral cancer of the mouth ﬂoor [63]. Recent reports
showed that SCCVII cells induce severe destruction of mandible
and zygoma when injected into the mouse masseter region [64].
To investigate the role of NF-B in bone invasion by OSCC, we
injected SCCVII cells into the masseter region of C3H/HeN mice
and then treated mice for 3 weeks with a selective NF-B inhibitor
E. Jimi et al. / Oral Science Inte
Fig. 3. Proposed mechanisms for how NF-B inhibition may  suppress bone invasion
by oral OSCCs. It has been hypothesized that inhibition of NF-B may  suppresses
bone invasion by three mechanisms: (i) an NF-B inhibitor directly suppresses the
proliferation and enhances apoptosis of OSCC cells; (ii) an NF-B inhibitor inhibits
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[steoclastogenesis by decreasing RANKL expression in stromal cells and by inhib-
ting RANK signaling in osteoclast precursors; and (iii) an NF-B inhibitor inhibits
atrix degradation by suppressing MMP  expression and production.
BD peptide [65]. NBD peptide treatment decreased zygoma and
andible destruction by SCCVII cells, reduced the number of osteo-
lasts by inhibiting RANKL expression in osteoblastic cells and
CCVII cells, increased apoptosis, and suppressed the proliferation
f SCCVII cells [65]. The NBD peptide also suppressed metastasis
nd tongue-speciﬁc tumor growth in GSAS/N5, a green ﬂuores-
ent protein (GFP)-labeled OSCC subline, -inoculated mice, and was
ccompanied by downregulation of NF-B-regulated metastasis-
elated genes, such as ﬁbronectin, 1 integrin, MMP-1, -2, -9, -14,
nd VEGF-C in engrafted tongue tumors [9].
Recently, synthesized agents IMD-0560 and its prodrug IMD-
560 have been shown to inhibit IKK activity under inﬂammatory
timuli that subsequently induce cytokine production. Several
eports showed that IMD-0560 inhibited NF-B activation in vitro
nd inﬂammatory models in vivo without any severe side effects
49,50,66,67]. Furthermore, a phase I study that assessed the efﬁ-
acy of IMD-2560 in rheumatoid arthritis has been completed
50]. IMD-0560 was shown to suppress TNF--induced nuclear
ranslocation of p65 and IB degradation in OSCC cells and
nhibit invasion of OSCC cells by suppressing MMP-9 production.
MD-0560 also prevented zygoma and mandible destruction by
CCVII cells, reduced the number of osteoclasts by inhibiting RANKL
xpression in osteoblastic cells and SCCVII cells, increased SCCVII
ell death, and suppressed proliferation and MMP-9 production in
CCVII cells [68]. Based on these results, IMD-0560 may  represent
 new therapeutic agent to prevent bone invasion by OSCC (Fig. 3).
. Conclusions and perspectives
Deregulation of NF-B activation drives malignant transfor-
ation through multiple mechanisms, including anti-apoptotic
ignaling, proliferation, acquired chemoresistance, invasion, and
etastasis in OSCC [7–14]. A previous report showed that elevated
xpression of NF-B correlates with enhanced invasion and metas-
asis of OSCC [11]. Although the therapeutic potential of NF-B
nhibition in OSCC has been extensively studied in vitro and in
ivo, use of genetic approaches or laboratory reagents to inhibit
F-B, such as dominant negative form of IKK or IBs, shRNA, pro-
easome inhibitors (MG132, lactacystin), IB inhibitor (DHMEQ),
KK inhibitors (PS-1145, Bay11-7042, NBD peptide), etc., has been
[
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limited for clinical application [50]. Because genetic deletion of
IKK or p65 is lethal in embryonic mice, careful consideration
should be given to the possibility that inhibition of NF-B may lead
to severe side effects [27–31]. To address this point, we  focused
on the potential use of bortezomib, curcumin, or IMD-0560 to
inhibit NF-B-driven bone invasion of OSCC in this review, because
bortezomib is the only drug currently under clinical development,
curcumin is a widely used food additive, and a phase I study of IMD-
0560 has been completed without severe side effects [56–62,68]. In
the case of mandibular bone invasion, where the tumor resides at
the body’s surface, it is possible to locally treat cancer with borte-
zomib, curcumin, or IMD-0560 and avoid any unexpected severe
side effects. Thus, it would be necessary to establish suitable pro-
tocols for the treatment of bone invasion by these compounds in
clinical application. It is also necessary to continue developing drug
repositioning in bone invasion by OSCC in the future.
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